

Special Issue

The Use of PSMA in Nuclear Medicine beyond Prostate Cancer

Message from the Guest Editors

In recent decades, the growing popularity of prostate-specific membrane antigen (PSMA) imaging for prostate cancer has resulted in the incidental discovery of abnormal uptakes associated with the presence of inflammatory, infectious, extra-prostatic neoplastic, and dysmetabolic diseases. As a result of these incidental findings, an increasing number of immunohistochemistry (IHC) studies and a deeper understanding of the mechanisms of expression of PSMA have been observed in several other normal tissues, non-neoplastic conditions and non-prostatic malignancies. This Special Issue aims to collect further scientific evidence on extra-prostatic tumors and benign pathologies that exhibit PSMA expression and can be studied with PSMA-based positron emission tomography (PET) as an additional or alternative tool to conventional imaging, with the aim of providing an overview of possible future applications of PSMA, both in diagnostic and theranostic settings. In this Special Issue, we will collect original articles, and reviews focused on novel insights into PSMA-PET and therapy in oncological and non-oncological fields.

Guest Editors

Dr. Virginia Liberini

Nuclear Medicine Department, S. Croce e Carle Hospital, 12100 Cuneo, Italy

Dr. Riccardo Laudicella

Unit of Nuclear Medicine, Biomedical Department of Internal and Specialist Medicine, University of Palermo, Palermo, Italy

Deadline for manuscript submissions

closed (31 December 2024)



Diagnostics

an Open Access Journal
by MDPI

Impact Factor 3.3
CiteScore 5.9
Indexed in PubMed



mdpi.com/si/181238

Diagnostics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
diagnostics@mdpi.com

[mdpi.com/journal/
diagnostics](https://mdpi.com/journal/diagnostics)





Diagnostics

an Open Access Journal
by MDPI

Impact Factor 3.3
CiteScore 5.9
Indexed in PubMed



[mdpi.com/journal/
diagnostics](https://mdpi.com/journal/diagnostics)



About the Journal

Message from the Editor-in-Chief

You are cordially invited to submit research articles, short communications, comprehensive reviews, case reports or interesting images for consideration and publication in *Diagnostics* (ISSN 2075-4418). *Diagnostics* is published in open access format – research articles, reviews and other contents are released on the Internet immediately after acceptance. The scientific community and the general public have unlimited and free access to the content as soon as it is published. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Andreas Kjaer

Department of Clinical Physiology, Nuclear Medicine & PET National
University Hospital, Rigshospitalet, University of Copenhagen,
Blegdamsvej 9, DK-2100 Copenhagen, Denmark

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, Inspec, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Internal Medicine)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).